Led by $880.85m asset transaction with Novasep Holding, Europe’s medical devices industry saw a rise of 0.55% in cross border deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 46 cross border deals worth $2.73bn were announced for the region during Q1 2021, against the last four-quarter average of 45.75 deals.
Of all the deal types, M&A saw most activity in Q1 2021 with 26 deals, representing a 56.5% share for the region.
In second place was venture financing with 16 deals, followed by private equity deals with four transactions, respectively capturing a 34.8% and 8.7% share of the overall cross border deal activity for the quarter.
In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.37bn, while private equity and venture financing deals totalled $212.52m and $148.41m, respectively.
Europe medical devices industry cross border deals in Q1 2021: Top deals
The top five medical devices cross border deals accounted for a 78.7% share of the overall value during Q1 2021.
The combined value of the top five cross border deals stood at $2.15bn, against the overall value of $2.73bn recorded for the quarter.
The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:
1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding
2) The $591m acquisition of Oxford Immunotec by PerkinElmer
3) Savaria’s $409.7m acquisition of Handicare Group
4) The $159m acquisition deal with Diagenode by Hologic
5) Sino Biopharmaceutical’s acquisition of Softhale for $110m.